Pricing Log in Create free account

Aprea Therapeutics, Inc. (APRE) vs Evogene Ltd. (EVGN)

Aprea Therapeutics, Inc. and Evogene Ltd. are both Biotechnology companies. Aprea Therapeutics, Inc. and Evogene Ltd. are of similar size ($6.2M and $6.0M). Evogene Ltd. grew revenue faster over the last twelve months: −73.6% against −81.0%. Aprea Therapeutics, Inc. has the higher net margin (0.00% vs −547.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Aprea Therapeutics, Inc. leads on 10 and Evogene Ltd. on 6.

Valuation

Metric APRE EVGN Biotechnology median
P/E n/m n/m 10.60
P/S 97.70 2.06 9.40
P/B 0.82 0.59 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.65 0.55 0.66
EV/Sales (34.76) (3.58) 9.02
Earnings yield (134.54%) (325.00%) (32.88%)
Free cash flow yield (45.64%) (315.60%) (23.13%)

Profitability

Metric APRE EVGN Biotechnology median
Gross margin 100.00% (67.59%) 68.51%
Operating margin 0.00% (851.42%) 0.00%
Net margin 0.00% (547.62%) 0.00%
Free cash flow margin 0.00% (650.63%) 0.00%
Return on equity (62.83%) (100.03%) (51.96%)
Return on assets (53.24%) (38.31%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric APRE EVGN Biotechnology median
Revenue growth (TTM) (80.99%) (73.63%) 6.76%
EPS growth (last fiscal year) 17.87% 62.63% 29.88%
Revenue growth, 5-year CAGR — 29.94% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric APRE EVGN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 9.67 3.57 4.97
Net debt to EBITDA 1.11 1.12 1.01

Dividend

Metric APRE EVGN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric APRE EVGN Biotechnology median
Market cap 6.24m 5.95m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack